Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KP104 in IgA Nephropathy and Complement 3 Glomerulopathy
NCT05517980Phase 2Recruiting
- Sponsor
- Kira Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of KP104 in IgA nephropathy (IgAN) and Complement 3 glomerulopathy (C3G) (6 cohorts), sponsored by Kira Pharmaceuticals. Primary endpoint: 24-hour urinary protein creatinine ratio at 24 weeks. Started Dec 2025; status: recruiting.
02
Drugs
KP104
03
Conditions
IgA nephropathy (IgAN)Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on NCT05517980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05517980.